From Blood to Brain Health: The Emerging Role of Neurofilament Light Chain (NfL) in Multiple Sclerosis and Beyond
Wednesday, September 30
Time 10:00 - 11:00 EDT | 15:00 – 16:00 BST | 23:00 – 24:00 KST
Multiple sclerosis (MS) remains one of the most complex neurological diseases to monitor and manage. While MRI and clinical assessment remain central to patient care, there is growing interest in blood-based biomarkers that may provide additional insight into disease activity and neuroaxonal injury. Neurofilament light chain (NfL) has emerged as one of the most widely studied biomarkers in this area, with increasing evidence supporting its role in multiple sclerosis research and evaluation.
This webinar, presented by Professor Tobias Sejbæk, will explore the scientific evidence behind NfL, its potential role alongside existing approaches to disease management, and the practical considerations involved in evaluating, validating, and implementing NfL testing in laboratory and clinical settings. Attendees will gain insight into the analytical considerations that influence assay confidence, the growing body of real-world evidence supporting NfL evaluation, and broader neurological applications of this emerging biomarker.
This session is intended for educational purposes only and not intended as communication regarding medical advice. Nothing in this presentation sould be used to diagnose or treat any disease or condition.
Key learning objectives:
- Describe how blood-based NfL may provide complementary information alongside MRI and how it is associated with neuroaxonal injury and disease activity in published studies.
- Identify key considerations for evaluating NfL testing in laboratory and clinical settings, including factors influencing interpretation and use alongside clinical and imaging data.
- Recognize the role of NfL as a general marker of axonal injury and its potential applications beyond relapsing multiple sclerosis in neurological research.
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
The following planners and faculty reported relevant financial relationship(s):
- Professor Tobias Sejbæk, MD, PhD
- All relevant financial relationships disclosed with Siemens Healthineers
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
- Instruction level: Intermediate
- Accreditation: P.A.C.E.® eligible
Registration is required to secure your place. If you register but can't attend live, you will receive a link to the on-demand recording once it becomes available.
Speakers
Who should attend?
- Clinical laboratorians
- Neurology-focused laboratory professionals
- Clinical researchers working in neurology
- Laboratory directors and managers
- Hospital and health-system decision-makers
- Stakeholders evaluating the adoption of novel biomarkers
- Professionals involved in assay implementation and laboratory workflow optimization
What will this webinar cover?
- Current approaches to monitoring and assessing multiple sclerosis.
- The biological significance of NfL as a marker of neuroaxonal injury.
- Published evidence linking NfL with disease activity, progression, and clinical outcomes in multiple sclerosis.
- How NfL may provide complementary information alongside MRI and clinical assessment.
- Analytical performance considerations, assay confidence, and factors influencing result interpretation.
- Key considerations for evaluating and validating NfL testing in laboratory settings.
- Real-world evidence and experiences associated with implementing NfL into clinical and laboratory workflows.
- Current and emerging applications of NfL across neurological research and disease management.
- Future directions for biomarker-driven approaches to neurological disease management.